{"entity":{"id":"paper-mejia-oneto-local-hydrogel-systemic-prodrug-sarcoma-acs-cent-sci-2016","kind":"paper","name":"Local drug activation by bioorthogonal chemistry: an implanted hydrogel and a systemic doxorubicin prodrug in a sarcoma xenograft","aka":["In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma"],"tldr":"The first demonstration, in mice, of the idea that became SQ3370: a material placed beside a tumour switches on a doxorubicin prodrug given into the blood.","summary":"Shasqi's founder and collaborators present an approach they name local drug activation: bioorthogonal chemistry is used to concentrate and activate a systemic small molecule at a chosen place. The method does not depend on cellular or environmental markers, only on a biomaterial implanted beforehand near the site. In mice carrying xenografts of HT1080, a soft tissue sarcoma line, a doxorubicin prodrug activated this way gave a clear therapeutic benefit over systemic therapy with minimal side effects.","asOf":"2026-11-16","links":[{"label":"ACS Cent Sci 2016","url":"https://doi.org/10.1021/acscentsci.6b00150"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/27504494/"},{"label":"Europe PMC (free full text)","url":"https://europepmc.org/article/MED/27504494"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["click-activated-prodrugs"],"targets":[],"drugs":[],"companies":["shasqi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo (company site, ClinicalTrials.gov v2, Crossref, Europe PMC, NIH RePORTER)","editedOn":"2026-11-16"},"journal":"ACS Central Science","year":2016,"doi":"10.1021/acscentsci.6b00150","pmid":"27504494","authors":"Mejia Oneto JM, Khan I, Seebald L, Royzen M","paperType":"basic","findings":["In mice with HT1080 soft tissue sarcoma xenografts, a doxorubicin prodrug activated at a pre-implanted biomaterial outperformed systemic therapy with minimal side effects; the abstract gives no figures."],"whatItMeans":"This is the origin of the approach, published four years before the first patient was treated.","caveats":["One xenograft model in mice; the abstract states no numbers.","Funded by Shasqi."],"changedPractice":false},"route":"/key-papers/paper-mejia-oneto-local-hydrogel-systemic-prodrug-sarcoma-acs-cent-sci-2016/","neighbours":{"technology":[{"id":"click-activated-prodrugs","kind":"technology","name":"Click-activated prodrugs (bioorthogonal drug activation in the body)","route":"/technologies/click-activated-prodrugs/"}],"company":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/"}],"drug":[{"id":"sq3370","kind":"drug","name":"SQ3370","route":"/drugs/sq3370/"}]}}